MARKET

CELC

CELC

Celcuity Inc
NASDAQ
104.51
-0.36
-0.34%
After Hours: 103.00 -1.51 -1.44% 16:21 02/13 EST
OPEN
105.05
PREV CLOSE
104.87
HIGH
107.75
LOW
103.16
VOLUME
400.32K
TURNOVER
--
52 WEEK HIGH
120.32
52 WEEK LOW
7.58
MARKET CAP
4.84B
P/E (TTM)
-28.4691
1D
5D
1M
3M
1Y
5Y
1D
Celcuity Inc. Files Initial Statement of Beneficial Ownership for Director Charles R. Romp
Reuters · 4h ago
Commit To Purchase Celcuity At $45, Earn 17.8% Using Options
NASDAQ · 9h ago
Celcuity Adds Veteran Director to Strengthen Oncology Strategy
TipRanks · 1d ago
*Celcuity Appoints Charles Romp to Its Bd of Directors
Dow Jones · 1d ago
Press Release: Celcuity Appoints Charles Romp to its Board of Directors
Dow Jones · 1d ago
Celcuity Appoints Charles Romp to Board of Directors
Reuters · 1d ago
Weekly Report: what happened at CELC last week (0202-0206)?
Weekly Report · 4d ago
Director Sells 20,000 Celcuity Shares for $2.4 Million Following 933% Share Price Jump
NASDAQ · 02/06 21:25
More
About CELC
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.

Webull offers Celcuity Inc stock information, including NASDAQ: CELC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CELC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CELC stock methods without spending real money on the virtual paper trading platform.